Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Galmed Pharmaceuticals ( (GLMD) ) just unveiled an announcement.
On May 13, 2025, Galmed Pharmaceuticals announced significant findings regarding their drug Aramchol, which demonstrated anti-fibrotic effects in pre-clinical models of primary sclerosing cholangitis (PSC). The results showed that Aramchol effectively attenuates and prevents biliary fibrosis, offering a potential therapeutic avenue for liver cancers associated with fibrosis. This development could enhance Galmed’s positioning in the biopharmaceutical industry, particularly in gastrointestinal oncology, and pave the way for further clinical studies.
Spark’s Take on GLMD Stock
According to Spark, TipRanks’ AI Analyst, GLMD is a Underperform.
Galmed Pharmaceuticals faces significant financial challenges, with no revenue and continuous losses, which heavily impact its stock score. Poor technical indicators and negative valuation metrics further weigh down the score. The strong equity position offers some support but is overshadowed by the lack of operational efficiency and profitability.
To see Spark’s full report on GLMD stock, click here.
More about Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing treatments for liver diseases and oncological indications. The company primarily develops Aramchol, targeting cardiometabolic diseases and gastrointestinal oncology, and is actively seeking to expand its product pipeline.
Average Trading Volume: 2,475,377
Technical Sentiment Signal: Sell
Current Market Cap: $2.89M
For a thorough assessment of GLMD stock, go to TipRanks’ Stock Analysis page.